Skip to main content

Qure

Category: AI in Healthcare

A global health-tech platform utilizing deep learning to provide automated interpretation of medical images including X-rays, CT scans, and ultrasounds. Qure was founded in 2016. The company is led by Prashant Warier. Based in Mumbai, India. Team size: 201-500. Total funding raised: $123.0M. Latest round: Series D. Key investors include Lightspeed Venture Partners, 360 ONE Asset, Novo Holdings, Peak XV Partners (formerly Sequoia India), MassMutual Ventures, Merck Global Health Innovation Fund.

Founded
2016
Headquarters
Mumbai, India
Team size
201-500
Total funding
$123.0M

Value proposition

Increases diagnostic accuracy and reduces turnaround time by triaging critical cases and automating routine screenings, particularly in resource-constrained environments.

Products and solutions

qXR: Automated chest X-ray screening for 30+ abnormalities including TB, lung nodules, and pleural effusion., qER: Emergency head CT scan triage for intracranial hemorrhages, infarcts, and fractures., qCT: Chest CT quantification for lung nodule management and COPD., qScout: An end-to-end patient management platform for screening and monitoring infectious diseases., qUnet: AI-powered point-of-care ultrasound (POCUS) for TB and pneumonia detection (currently under development via Gates Foundation grant).

Unique value

Combines high-end clinical triage for developed markets with a robust 'Global Health' focus, specifically optimized for low-resource settings and mobile screening units.

Target customer

Hospitals, diagnostic imaging centers, public health agencies, NGOs (e.g., Stop TB Partnership), and medical device OEMs.

Industries served

Healthcare & Diagnostics, Public Health, Medical Devices, Tele-radiology, Pharmaceuticals (Clinical Trials)

Technology advantage

Proprietary deep learning models trained on a massive, diverse dataset of over 10 million images; holds 16+ FDA clearances and extensive CE marks, ensuring high regulatory barriers to entry.

How they differentiate

Qure differentiates through a dual-focus strategy: high-end clinical triage for developed markets (e.g., stroke and lung cancer) and a dominant 'Global Health' vertical specialized in infectious diseases like Tuberculosis, optimized for low-resource settings and mobile screening.

Main competitors

Lunit, Aidoc, Viz.ai, Annalise.ai

Key partnerships

Bill & Melinda Gates Foundation (Grant-funded R&D for Ultrasound AI, Jan 2026), Microsoft (Precision Imaging Network integration for lung cancer, Nov 2025), Johnson & Johnson MedTech (Project BreatheEZ — Incidental Pulmonary Nodule clinics in India, May 2025), AstraZeneca (Lung Ambition Alliance + Telangana MoU for lung cancer screening, Apr 2026), VillageReach (AI-enabled pandemic preparedness in Mozambique, May 2026), Stop TB Partnership (Global TB screening initiatives), Strategic OEM integrations with Fujifilm, GE Healthcare, and Roche Diagnostics

Notable customers

NHS (UK), AstraZeneca, Fujifilm, Stop TB Partnership, Roche Diagnostics

Major milestones

Secured 26 FDA clearances across 9 products for X-ray and CT (Feb 2026) including qXR-Detect, Recognized among TIME's 100 Most Influential Companies of 2025, Closed $65M Series D funding round in September 2024, Awarded Bill & Melinda Gates Foundation grant (Jan 2026) for AI-powered point-of-care ultrasound, Strategic partnerships with Microsoft (Nov 2025) and Johnson & Johnson MedTech (May 2025)

Growth metrics

Impacted over 45 million lives across 105+ countries; deployed at 5,500+ healthcare sites globally.

Market positioning

A global leader in AI-driven medical imaging diagnostics, positioned as a bridge between advanced radiology automation and large-scale public health screening initiatives.

Geographic focus

Global presence with primary operations in India, United Kingdom, United States, Southeast Asia, and Sub-Saharan Africa.

Patents and IP

Holds multiple patents related to automated medical image analysis, neural network architectures for radiology, and deep learning-based detection of abnormalities in X-rays and CT scans.

About Prashant Warier

Prashant Warier is the CEO and Co-founder of Qure. He has over 20 years of experience in architecting and commercializing AI solutions. Prior to founding Qure in 2016, he spent nearly a decade at Fractal Analytics as Chief Data Scientist, where he led the data science practice. He also served as a Senior Scientist at SAP, focusing on supply chain cross-functional optimization. He holds a PhD in Operations Research from Georgia Institute of Technology and a B.Tech from IIT Delhi.

Official website: